Sunitinib, an oral small-molecule multitargeted tyrosine kinase inhibitors (TKIs), exerts dual effects on anti-tumor angiogenesis and anti-tumor cell proliferation via inhibiting the vascular endothelial growth factor-1, 2, 3 (VEGF-1, 2, 3), the platelet-derived growth factor-α, β (PDGFr-α, β), the stem-cell growth factor receptor (KIT), colony-stimulating factor (CSF)-1R, FMS-like tyrosine kinase-3 (FLT-3), and the rearranged during transfection (RET) (Mena et al., 2010). Here, CSF1R is linked to neoplasm.